Supplementary material for Visser et al., Cardiac monitoring during adjuvant trastuzumab therapy: Guideline adherence in clinical practice, Acta Oncol, 2015; doi:10.3109/0284186X.2015.1068444.

Supplementary Table I. Summary of the Dutch guideline breast cancer 2008 (Source: *Richtlijn mammacarcinoom, NABON 2008*).

Chemotherapy	
Indicated	If ER- and PR-: • Until age 70; N+ as well as unfavorable N0 If ER+ and/or PR+: • Until age 70; N+ as well as unfavorable N0
Chemotherapy	HER2 + tumor: • N+ and unfavorable N0 • 4x q3wk AC + 12x q1wk paclitaxel + trastuzumab (weekly) → trastuzumab (weekly) + RT → trastuzumab until 1 year OR • 6x anthracycline- or anthracyline-taxane containing chemotherapy followed by 1 year trastuzumab
Trastuzumab	
Indicated	HER2+++ (IHC) and/or FISH+; LVEF ≥ 55% before start trastuzumab therapy
Measurements	Check LVEF before the start of chemotherapy and before the start of trastuzumab and every 3 months until the end of trastuzumab therapy. If LVEF ≥ 50% and did not decrease > 10 EF points from baseline; trastuzumab treatment can be continued.

Supplementary Table II. Characteristics of patients treated (n = 171) vs. not treated (n = 44) with trastuzumab.

	Patients treated with trastuzumab (N = 171) Mean (sd)	Patients not treated with trastuzumab (N = 44) Mean (sd)	P-value
Age	51.1 (10.4)	57.6 (7.7)	< 0.001*
Charlson score	0.5 (1.1)	1.7 (2.0)	0.011*
	N (%)	N (%)	
Grade			0.32
1	5 (2.9)	0 (0)	
2	36 (21.1)	14 (31.8)	
3	107 (62.6)	25 (56.8)	
unknown	23 (13.5)	5 (11.4)	
Stadium			0.46
1	59 (34.5)	11 (25.0)	
2	74 (43.3)	22 (50.0)	
3	38 (22.2)	11 (25.0)	
Surgery			0.67
Yes	168 (98.2)	35 (79.5)	
No	3 (1.8)	1 (2.3)	
Unknown		8 (18.2)	
Type of surgery			0.22
Lumpectomy + sentinel node biopsy	29 (17.0)	9 (25.7)	
Mastectomy + sentinel node biopsy	28 (16.4)	3 (8.6)	
Lumpectomy + lymph node dissection	17 (9.9)	4 (11.4)	
Mastectomy + lymph node dissection	85 (49.7)	13 (37.1)	
Other	8 (4.7)	4 (11.4)	
Unknown	4 (2.3)	10 (28.6)	
Radiotherapy			0.96
Yes	108 (63.2)	22 (50.0)	
No	63 (36.8)	13 (29.5)	
Unknown		9 (20.5)	
Hormone therapy			0.76
Yes	89 (52.0)	17 (38.6)	
No	82 (48.0)	18 (40.9)	
Unknown		9 (20.5)	
(Neo) adjuvant chemotherapy			< 0.001*
Yes	171 (100.0)	15 (34.1)	
No		20 (45.0)	
Unknown		9 (20.5)	

*p < 0.05.